Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Freddie Mac Stock: A Volatile Cocktail of Value and Uncertainty

Felix Baarz by Felix Baarz
November 17, 2025
in Analysis, IPOs, Mergers & Acquisitions, Penny Stocks, Real Estate & REITs
0
Freddie Mac Stock
0
SHARES
106
VIEWS
Share on FacebookShare on Twitter

Freddie Mac shares are caught in a powerful tug-of-war. On one side, the stock appears fundamentally undervalued to an extreme degree, while on the other, political maneuvering and persistent financial losses fuel wild price swings. The mortgage giant’s future is a subject of intense debate, caught between billionaire Bill Ackman’s merger ambitions and the Trump administration’s push for a public offering.

Political Forces Drive Market Swings

The most significant price movements for Freddie Mac are politically driven. Billionaire investor Bill Ackman has scheduled a livestream for November 18th, where he intends to discuss a potential merger between Fannie Mae and Freddie Mac. Simultaneously, the Trump administration is pressuring for an initial public offering (IPO) for both government-sponsored enterprises by year’s end. This political uncertainty recently demonstrated its market impact: the stock plummeted by 25% at one point before paring losses to close down 5.4%.

A Rollercoaster Trading Pattern

The equity is currently trading at $8.13 after gaining 3.70% intraday. However, this brief rally is deceptive. Over the past seven trading sessions, the shares have declined by 16.10%, and over a 30-day period, they are down 17.29%. The volatility is staggering, especially when contrasted with a remarkable 141.25% gain over the past year and a three-year return exceeding 1,500%. Presently, the stock trades 45.76% below its 52-week high, yet it remains 283.49% above its low, illustrating a dramatic pattern of peaks and valleys.

Should investors sell immediately? Or is it worth buying Freddie Mac?

Fundamental Concerns Persist

The company’s third quarter delivered a net income of $2.8 billion, though this represented an 11% decrease compared to the same period last year. While net interest income climbed 9% to $5.5 billion, the enterprise continues to operate at a loss. Over the last five years, its losses have deepened at an annualized rate of 48.5%. The anticipated revenue growth rate of 2.7% per year falls significantly below the U.S. market average of 10.3%.

  • Valuation at Discounted Levels:
    • P/E ratio sits at just 1.2x to 1.3x
    • Substantially below the industry average of 3.7x to 4.1x
    • Also undercuts the financial industry average of 2.4x
    • A discounted cash flow (DCF) model calculates a fair value of $119.21 per share

Mortgage Market Shows Mixed Signals

The U.S. housing market is presenting conflicting indicators. The average 30-year fixed mortgage rate increased slightly to 6.24%, while the 15-year rate saw a minimal decline to 5.49%. On a positive note, both rates remain below last year’s levels of 6.78% and 5.99%, respectively. Homebuying activity is displaying initial signs of recovery, but the critical question remains whether this is sufficient to establish a sustainable trend reversal.

The central dilemma for investors is whether the fundamental undervaluation will ultimately prevail or if political uncertainty will continue to dictate the stock’s direction. The coming days are likely to set a course that could influence the equity’s performance for months to come.

Ad

Freddie Mac Stock: Buy or Sell?! New Freddie Mac Analysis from March 25 delivers the answer:

The latest Freddie Mac figures speak for themselves: Urgent action needed for Freddie Mac investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Freddie Mac: Buy or sell? Read more here...

Tags: Freddie Mac
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Watsco Stock
Analysis

Watsco’s Dividend Hike Contrasts with Operational Headwinds

March 25, 2026
Oracle Stock
AI & Quantum Computing

Oracle’s Backlog Soars on Cloud and AI Contract Momentum

March 25, 2026
Ocugen Stock
Analysis

Ocugen Shares Tumble Despite Positive Clinical Trial Results

March 25, 2026
Next Post
Johnson & Johnson Stock

Johnson & Johnson Shares Approach Record Territory

Tesla Stock

Tesla Gains Breathing Room in Critical Battery Supply Dispute

Freeport-McMoRan Stock

Freeport-McMoRan's Critical Juncture: Navigating Production Crisis and Legal Challenges

Recommended

Biotechnology Market Capitalization

Improvement in Market Sentiment for Adagene as Short Interest Decreases

2 years ago
Airbnb Stock

Airbnb Faces Dual Challenges as Insiders Sell and Fee Structure Shifts

7 months ago
Kraft Heinz Stock

Kraft Heinz Faces Mounting Analyst Skepticism as Price Targets Slashed

5 months ago
Nestle Stock

Nestlé Shares: A Clash of Analyst Views Creates Market Uncertainty

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Oracle’s Backlog Soars on Cloud and AI Contract Momentum

Regulatory Scrutiny Looms Over Alphabet’s Aggressive AI Expansion

Ocugen Shares Tumble Despite Positive Clinical Trial Results

Regulatory Proposal Sparks Sell-Off in Coinbase Shares

UnitedHealth Faces Multifaceted Regulatory Scrutiny Ahead of Earnings

Intel’s Capital Reshuffle and Leadership Transition Revealed in Annual Filing

Trending

Watsco Stock
Analysis

Watsco’s Dividend Hike Contrasts with Operational Headwinds

by SiterGedge
March 25, 2026
0

Watsco, a leading distributor of heating and cooling equipment, is sending a strong signal of confidence by...

Pinduoduo Stock

Pinduoduo’s Upcoming Earnings: A Critical Test for the E-Commerce Giant

March 25, 2026
XPeng Stock

XPeng Achieves Profitability Milestone Amid Strategic Mexican Launch

March 25, 2026
Oracle Stock

Oracle’s Backlog Soars on Cloud and AI Contract Momentum

March 25, 2026
Alphabet Stock

Regulatory Scrutiny Looms Over Alphabet’s Aggressive AI Expansion

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Watsco’s Dividend Hike Contrasts with Operational Headwinds
  • Pinduoduo’s Upcoming Earnings: A Critical Test for the E-Commerce Giant
  • XPeng Achieves Profitability Milestone Amid Strategic Mexican Launch

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com